Shareholders to Vote on Strategic Pivot, Massive Dilution Authorization, and Executive Compensation Hike
QUCY has more than doubled off its 52-week low of $0.3.
Summary
Quantum Cyber N.V. is asking shareholders to approve a major business pivot to cyber/drones, grant broad authority for future share issuances with pre-emption rights exclusion, and significantly increase director compensation, including up to 10 million shares annually for the Board. These approvals are critical for the company's survival and the closing of a recent private placement.
Key Events · Corporate Governance and Compliance · QUCY
-
Strategic Business Pivot Approval
Shareholders will vote to approve the Board's resolution to expand activities into quantum computing and next-generation cybersecurity, and to amend the Articles of Association to reflect this new strategic direction. This formalizes a major shift previously announced.
-
Broad Share Issuance Authorization
The Board seeks an extension until June 28, 2031, to issue all unissued shares of the authorized capital and to limit or exclude pre-emption rights. This grants significant power for future dilutive capital raises, adding to the existing $100 million ATM program.
-
Substantial Director Compensation Increase
Proposed amendments to the remuneration policy include increasing the annual share/rights grant for the Board from 500,000 to 10,000,000 shares under the 2025 Omnibus Incentive Plan, and doubling non-executive directors' fixed annual remuneration from $50,000 to $100,000. This represents a potential dilution of over 68% of the current market cap for board compensation alone.
-
Critical for Private Placement Closing
The approval of these proposals is a condition precedent to the 'Final Closing' of a $6 million private placement with David E. Lazar, who recently acquired preferred shares convertible into 97.4% of the company's outstanding shares.
Analysis · QUCY · Life Sciences
Quantum Cyber N.V. is seeking shareholder approval for a series of critical proposals at its upcoming Annual General Meeting on June 29, 2026. These include formalizing a radical business pivot from life sciences to quantum computing and cybersecurity, extending the Board's authority to issue all unissued shares and exclude pre-emption rights, and significantly increasing executive and non-executive director compensation. The proposed remuneration policy would allow the Board to receive up to 10,000,000 shares or rights annually, representing a potential dilution of over 68% of the current market capitalization for compensation alone. These approvals are crucial as they are conditions precedent to the final closing of a recent $6 million private placement, which saw David E. Lazar acquire preferred shares convertible into 97.4% of the company's outstanding shares. The company has previously disclosed substantial doubt about its ability to continue as a going concern, making these measures vital for its survival but highly dilutive for existing public shareholders.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QUCY was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.8M. The 52-week trading range was $0.30 to $4.93. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.